How to buy Algernon Pharmaceuticals (AGNP) stock when it goes public

Algernon Pharmaceuticals stock is currently available to purchase as an over-the-counter (OTC) stock on the OTCQB. But many popular brokerages don't offer access to OTC stocks.

Algernon Pharmaceuticals has recently filed with the US Securities and Exchange Commission (SEC) to list its stock on the Nasdaq Capital Market. This will make it possible to buy the stock from any major stockbroker.

What we know about Algernon Pharmaceuticals stock

Algernon Pharmaceuticals filed a draft registration with the SEC to trade on the Nasdaq under the ticker symbol AGNP. If approved, this will make the stock more accessible to new investors.

As of on February 16, the stock cost $5.10 on the OTCQB, but that doesn't necessarily mean the price will be the same once it's available on a more popular exchange. There's no news yet about how much the stock will cost when it goes live on the Nasdaq. No date has been set for when the stock will be available on the Nasdaq.

How to buy shares in Algernon Pharmaceuticals

Once Algernon Pharmaceuticals is available on Nasdaq Capital Market, you can buy shares using an account with any major brokerage. Consider opening a brokerage account today so you're ready as soon as the stock hits the market.

1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
2. Open your brokerage account. Complete an application with your details.
3. Confirm your payment details. Fund your account.
4. Research the stock. Find the stock by name or ticker symbol – AGNP – and research it before deciding if it's a good investment for you.
5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.

Finder's picks for buying Algernon Pharmaceuticals stock when it goes public

Best for beginners

Go to site

Commission-free stock trading

• No-cost financial planning and automated investing
• $0 commission on stocks, ETFs and options
• Get up to $1,000 in stock when you fund a new account within 30 days

Top pick for new account bonus

Go to site

$200 in US stocks

• Trade options, futures, options on futures, stocks, ETFs
• $0 commission to close options
• Get $100-$5,000 when you open an account with $5,000 to $1,000,000+

Top pick for interest on uninvested cash

Go to site

Easy access to diverse assets

• Trade stocks, bonds, options, ETFs, crypto, Treasurys, collectibles, royalties
• Earn 5.1% APY on your cash
• Earn a $0.18 rebate on options, with no commissions and no per-contract fees

How do similar companies perform?

It's impossible to predict how any stock will perform — and IPOs can be particularly volatile. Looking at the performance of similar companies can help you decide if now is a good time to buy Algernon Pharmaceuticals stock.

• Biogen (BIIB.US)

  Company summary

  Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

  Historical performance

  Stock information

  • Market capitalization: $31467878400
  • P/E ratio: 27.0163
  • PEG ratio: 6.2424
  • Dividend yield: N/A%

  Get more detailed information and learn how to buy BIIB.US stock

• Vertex Pharmaceuticals (VRTX.US)

  Company summary

  Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

  Historical performance

  Stock information

  • Market capitalization: $102732292096
  • P/E ratio: 28.6575
  • PEG ratio: 0.5342
  • Dividend yield: N/A%

  Get more detailed information and learn how to buy VRTX.US stock

• Gilead Sciences (GILD.US)

  Company summary

  Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

  Historical performance

  Stock information

  • Market capitalization: $81689010176
  • P/E ratio: 181.9722
  • PEG ratio: 0.421
  • Dividend yield: 0.047%

  Get more detailed information and learn how to buy GILD.US stock

Compare trading platforms

1 - 6 of 6

Sort by:

Name	Product	Ratings	Available asset types	Minimum deposit	Stock trade fee	Cash sweep APY	Signup bonus
SoFi Invest® Finder Score: 4.2 / 5: ★★★★★ SoFi Invest® Finder Score: 4.2 / 5: ★★★★★		★★★★★	Stocks, Mutual funds, ETFs, Alternatives	$0	$0		Get up to $1,000 in stock when you fund a new Active Invest account	Go to site More Info		loading Fetching your data...
Tastytrade Finder Score: 4.6 / 5: ★★★★★ Tastytrade Finder Score: 4.6 / 5: ★★★★★		★★★★★	Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills	$0	$0	N/A	Get $100-$5,000 when you open and fund an account with $5,000 to $1,000,000+	Highly commended for Best Derivatives Trading Platform award.	Go to site More Info		loading Fetching your data...
Public.com Finder Score: 4.2 / 5: ★★★★★ Public.com Finder Score: 4.2 / 5: ★★★★★		★★★★★	Stocks, ETFs, Cryptocurrency, Art, Treasury Bills, Collectibles	$0	$0	5.1%	N/A	2.5% fee applies to all alternative asset transactions.	Go to site More Info		loading Fetching your data...
Robinhood Gold Finder Score: 4.3 / 5: ★★★★★ Robinhood Gold Finder Score: 4.3 / 5: ★★★★★		★★★★★	Stocks, Options, ETFs, Cryptocurrency	$0	$0	5%	Get a free stock when you successfully sign up and link your bank account.	Try Robinhood Gold for 30 days risk-free upon signup and earn a 5% APY on your uninvested cash, a 3% match on IRA contributions, up to $50,000 in instant deposits and more. Accounts are auto-downgraded after the trial period. Robinhood Gold is $5/month.	Go to site More Info		loading Fetching your data...
Moomoo Finder Score: 4.7 / 5: ★★★★★ Moomoo Finder Score: 4.7 / 5: ★★★★★ Exclusive		★★★★★	Stocks, Options, ETFs	$0	$0	5.10%	Choose a 1.5% match or 7 free fractional shares when you open a new account and meet funding requirements	No commission stock and ETF trading, with a chance to get a 1.5% cash reward match or 7 free fractional shares.	Go to site More Info		loading Fetching your data...
Robinhood Finder Score: 4.4 / 5: ★★★★★ Robinhood Finder Score: 4.4 / 5: ★★★★★		★★★★★	Stocks, Options, ETFs, Cryptocurrency	$0	$0	1.5%	Get a free stock when you successfully sign up and link your bank account.	Trade stocks, options, ETFs and crypto without commissions on a user-friendly platform and earn 1.5% APY on your uninvested cash.	Go to site More Info		loading Fetching your data...

loading

CompareClear

More on investing

How to buy FAANG stocks

Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.

Read more…

How to buy soccer stocks

A simple guide to buying stocks in your favorite European soccer team.

Read more…

Inflation stocks

Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.

Read more…